XML 131 R82.htm IDEA: XBRL DOCUMENT v3.21.1
Income Tax - Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit (Details) - EUR (€)
€ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disclosure Of Major Components Of Tax Expense Income [Line Items]      
Loss before tax € (145,802) € (179,440) € (47,662)
Expected tax benefit (based on BioNTech`s statutory tax rate of 30.79%, 2019: 30.78%, 2018: 30.99%) 44,891 55,240 14,776
Effects      
Government grants exempted from taxes 14 48 28
Non-deductible expenses (770) (58) (18)
Add-back for trade tax purposes (595) (110) (96)
Non-tax effective bargain purchase 2,156    
Non-recognition of tax effect on share-based payment expenses (9,806) (9,308)  
Tax-effective equity transaction costs 10,229 5,121  
Utilization of tax losses     1,165
Non-recognition of deferred taxes on tax losses and temporary differences (12,961) (51,197) (13,634)
Effect from lower foreign income tax rate (1,304) (102)  
Adjustment prior year tax (326) 316  
Tax credit 1,059    
Other effects (59) 126 (2,821)
Income taxes 161,000 268 € (600)
Tax Losses      
Effects      
Recognition of deferred taxes not recognized in prior periods 102,231    
Temporary Differences      
Effects      
Recognition of deferred taxes not recognized in prior periods € 26,241 € 192